CTLA4 and cancer: Finally, memory Th1 and Tc1 immune responses directed against immunogenic bacteria E. hirae, A. muciniphila, and B. fragilis dictated progression free survival in cancer patients treated with anti-PD-1 or anti-CTLA-4 Abs (210, 243).